Cytek Biosciences, Inc.
CTKB
$3.77
-$0.05-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 11.60% | 10.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 11.60% | 10.47% | |||
| Cost of Revenue | 5.91% | 6.20% | |||
| Gross Profit | 16.02% | 14.03% | |||
| SG&A Expenses | 0.74% | -2.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.41% | 1.10% | |||
| Operating Income | 109.09% | 50.18% | |||
| Income Before Tax | 6,475.16% | 102.18% | |||
| Income Tax Expenses | 186.73% | -124.14% | |||
| Earnings from Continuing Operations | 924.76% | 109.02% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 924.76% | 109.02% | |||
| EBIT | 109.09% | 50.18% | |||
| EBITDA | 193.45% | 64.33% | |||
| EPS Basic | 937.50% | 109.07% | |||
| Normalized Basic EPS | 5,242.86% | 102.05% | |||
| EPS Diluted | 890.28% | 109.00% | |||
| Normalized Diluted EPS | 5,242.86% | 102.05% | |||
| Average Basic Shares Outstanding | -1.47% | -0.33% | |||
| Average Diluted Shares Outstanding | -2.79% | 1.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||